Group 1 - The company raised a total of RMB 1,480 million by issuing 37 million shares at RMB 40.00 per share, with net proceeds after fees amounting to RMB 1,381 million [2][3][4] - The company has established a dedicated account for managing the raised funds, adhering to regulatory requirements and ensuring investor protection [3][4][5] - As of December 31, 2024, the company has one dedicated fund account for the raised capital [5] Group 2 - The company has utilized excess raised funds for various projects, including the expansion of production facilities, with specific projects like the extraction workshop renovation and the construction of a new building [6][7][8][9] - The company has permanently supplemented its working capital with remaining excess funds from several projects, totaling RMB 7,819 million [11][12] Group 3 - The company reported a net profit of RMB 33.62 million for the year 2024, with the parent company showing a net loss of RMB 15.02 million [28] - The profit distribution plan for 2024 includes no cash dividends, stock bonuses, or capital increases, with retained earnings to be carried forward [26][28][29] Group 4 - The company has undergone changes in accounting policies in accordance with new regulations issued by the Ministry of Finance, effective from January 1, 2024 [31][32][34] - The company has corrected prior accounting errors related to unrecorded sales expenses, amounting to RMB 288.45 million, without affecting current profits [45][46] Group 5 - The company plans to renew its contract with Tianjian Accounting Firm for the 2025 financial audit, citing their experience and compliance with regulatory standards [57][58][59] - The audit fee for the 2024 financial report is set at RMB 2.13 million, subject to approval by the shareholders' meeting [65][66]
贵州百灵企业集团制药股份有限公司 关于募集资金年度存放与使用情况的专项报告